• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

简短通讯:开始联合抗逆转录病毒治疗的HIV感染者中禁忌药物相互作用与随后住院之间的关系

Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy.

作者信息

Sangiovanni Ryan J, Jakeman Bernadette, Nasiri Mona, Ruth Lindsey, Mahatme Sheran, Patel Nimish

机构信息

1 Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, South Carolina.

2 Departments of Pharmacy and Research, Stratton Veterans' Affairs Medical Center, Albany, New York.

出版信息

AIDS Res Hum Retroviruses. 2019 May;35(5):430-433. doi: 10.1089/AID.2018.0205. Epub 2019 Feb 27.

DOI:10.1089/AID.2018.0205
PMID:30612438
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6508060/
Abstract

Persons living with HIV (PLWH) are at an increased risk of contraindicated drug-drug interactions (XDDIs), which may result in deleterious outcomes. Study objectives were to (1) compare the frequency of hospitalizations between patients with and without XDDIs and (2) determine if XDDIs are independently associated with hospitalizations in PLWH. A retrospective cohort study was performed among PLWH receiving care at the Upstate New York Veterans' Healthcare Administration or University of New Mexico Truman Health Services from 2000 to 2013. Hospitalization was defined as an admission to an inpatient hospital facility for ≥24 h. Of the 1329 patients evaluated, 149 (11.2%) patients were hospitalized within 1 year of antiretroviral therapy initiation. A significantly higher proportion of patients with XDDIs were hospitalized compared with those who did not have XDDIs (20.3% vs. 10.2%, risk ratio: 1.98, 95% confidence interval [CI]: 1.35-2.91,  = .001). In the multivariate Cox proportional hazards regression analyses, XDDIs were independently associated with hospitalizations (hazard ratio [HR]: 1.58; 95% CI: 1.00-2.48;  = .05), after adjustment for CD4 < 242 cells/mm (HR: 2.38; 95% CI: 1.72-3.33;  < .001), protease inhibitor (PI)-based regimen (HR: 1.35; 95% CI: 0.97-1.89;  = .08), recreational drug use (HR: 2.58, 95% CI: 1.85-3.58,  < .001), and non-HIV medications ≥10 (HR: 1.62; 95% CI: 0.97-2.69;  = .07). In this study an increased risk of hospitalization was observed among PLWH with XDDIs compared with those without XDDIs. This relationship persisted after adjustment for CD4 count, use of a PI-based regimen, recreational drug use, and number of non-HIV medications.

摘要

艾滋病毒感染者(PLWH)发生禁忌药物相互作用(XDDIs)的风险增加,这可能会导致有害后果。研究目的是:(1)比较有和没有XDDIs的患者之间的住院频率;(2)确定XDDIs是否与PLWH的住院独立相关。对2000年至2013年在纽约州北部退伍军人医疗管理局或新墨西哥大学杜鲁门健康服务中心接受治疗的PLWH进行了一项回顾性队列研究。住院定义为入住住院医院设施≥24小时。在评估的1329名患者中,149名(11.2%)患者在开始抗逆转录病毒治疗的1年内住院。与没有XDDIs的患者相比,有XDDIs的患者住院比例显著更高(20.3%对10.2%,风险比:1.98,95%置信区间[CI]:1.35 - 2.91,P = 0.001)。在多变量Cox比例风险回归分析中,在调整了CD4<242细胞/mm³(风险比[HR]:2.38;95% CI:1.72 - 3.33;P<0.001)、基于蛋白酶抑制剂(PI)的治疗方案(HR:1.35;95% CI:0.97 - 1.89;P = 0.08)、使用娱乐性药物(HR:2.58,95% CI:1.85 - 3.58,P<0.001)和非艾滋病毒药物≥10种(HR:1.62;95% CI:0.97 - 2.69;P = 0.07)之后,XDDIs与住院独立相关(HR:1.58;95% CI:1.00 - 2.48;P = 0.05)。在本研究中,与没有XDDIs的PLWH相比,有XDDIs的PLWH住院风险增加。在调整了CD4计数、基于PI的治疗方案的使用、娱乐性药物的使用和非艾滋病毒药物的数量后,这种关系仍然存在。

相似文献

1
Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy.简短通讯:开始联合抗逆转录病毒治疗的HIV感染者中禁忌药物相互作用与随后住院之间的关系
AIDS Res Hum Retroviruses. 2019 May;35(5):430-433. doi: 10.1089/AID.2018.0205. Epub 2019 Feb 27.
2
Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.比较HIV感染患者不同抗逆转录病毒治疗方案中禁忌药物相互作用的频率。
Ann Pharmacother. 2017 May;51(5):365-372. doi: 10.1177/1060028016685115. Epub 2016 Dec 20.
3
Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.在合并感染HIV和丙型肝炎的患者用药清单中添加含simeprevir或sofosbuvir的治疗方案后药物相互作用的发生率
AIDS Res Hum Retroviruses. 2015 Feb;31(2):189-97. doi: 10.1089/AID.2014.0215. Epub 2015 Jan 6.
4
Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patients.比较单感染患者中不同丙型肝炎治疗方案的药物相互作用频率。
Ann Hepatol. 2019 Jul-Aug;18(4):601-606. doi: 10.1016/j.aohep.2019.01.005. Epub 2019 May 4.
5
Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.识别接受高效抗逆转录病毒治疗及伴随用药的印度艾滋病毒感染者中具有临床意义的药物相互作用的潜在风险因素。
Int J Risk Saf Med. 2017;29(1-2):25-55. doi: 10.3233/JRS-170738.
6
Hospital days attributable to immune reconstitution inflammatory syndrome in persons living with HIV before and after the 2012 DHHS HIV guidelines.2012年美国卫生与公众服务部(DHHS)发布HIV指南前后,HIV感染者因免疫重建炎症综合征导致的住院天数。
AIDS Res Ther. 2017 May 2;14:25. doi: 10.1186/s12981-017-0152-0. eCollection 2017.
7
Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.药丸负担对接受抗逆转录病毒治疗的艾滋病毒感染和艾滋病患者的依从性、住院风险及病毒抑制的影响
Pharmacotherapy. 2016 Apr;36(4):385-401. doi: 10.1002/phar.1728. Epub 2016 Apr 13.
8
Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).极晚期HIV感染(CD4<50/mm³)患者采用基于蛋白酶抑制剂的治疗方案的住院情况及治疗费用。
HIV Clin Trials. 2000 Sep-Oct;1(2):9-16. doi: 10.1310/6ulm-xyb7-h4xp-bhfj.
9
Use of comedications and potential drug-drug interactions in people living with HIV in China.中国艾滋病毒感染者中合并用药情况及潜在药物相互作用
J Infect Chemother. 2020 Jul;26(7):722-728. doi: 10.1016/j.jiac.2020.04.003. Epub 2020 Apr 27.
10
Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.老年和年轻HIV感染者的多重用药及药物相互作用:罂粟花研究
Antivir Ther. 2019;24(3):193-201. doi: 10.3851/IMP3293.

引用本文的文献

1
Polypharmacy and Aging in People Living with HIV: 6 Years of Experience in a Multidisciplinary Outpatient Clinic.多药治疗与 HIV 感染者老龄化:多学科门诊 6 年经验。
Drugs Aging. 2023 Jul;40(7):665-674. doi: 10.1007/s40266-023-01037-1. Epub 2023 Jun 13.
2
Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study.多药治疗相关的住院风险在伴有和不伴有 HIV 的老年人群体中:一项观察性研究。
Lancet Healthy Longev. 2021 Oct;2(10):e639-e650. doi: 10.1016/S2666-7568(21)00206-3. Epub 2021 Sep 29.
3
High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.HIV 感染和勃起功能障碍男性患者中潜在磷酸二酯酶 5 抑制剂药物相互作用的频率较高。
PLoS One. 2021 May 6;16(5):e0250607. doi: 10.1371/journal.pone.0250607. eCollection 2021.
4
Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients.在接受过治疗的患者中,将抗逆转录病毒疗法转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺前后药物相互作用的发生率和严重程度。
Open Forum Infect Dis. 2020 Dec 18;8(1):ofaa625. doi: 10.1093/ofid/ofaa625. eCollection 2021 Jan.

本文引用的文献

1
Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.比较HIV感染患者不同抗逆转录病毒治疗方案中禁忌药物相互作用的频率。
Ann Pharmacother. 2017 May;51(5):365-372. doi: 10.1177/1060028016685115. Epub 2016 Dec 20.
2
Hospitalization rates of people living with HIV in the United States, 2009.2009 年美国艾滋病毒感染者的住院率。
Public Health Rep. 2014 Mar-Apr;129(2):178-86. doi: 10.1177/003335491412900212.
3
Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.年龄与 HIV 阳性患者的多种药物治疗和与抗逆转录病毒药物相互作用风险的关联。
Ann Pharmacother. 2013 Nov;47(11):1429-39. doi: 10.1177/1060028013504075.
4
Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.老龄化 HIV 感染人群中,多种药物并用与抗逆转录病毒药物相互作用的风险。
J Gen Intern Med. 2013 Oct;28(10):1302-10. doi: 10.1007/s11606-013-2449-6. Epub 2013 Apr 20.
5
Ageing with HIV: medication use and risk for potential drug-drug interactions.HIV 感染者的老龄化:药物使用与潜在药物相互作用风险。
J Antimicrob Chemother. 2011 Sep;66(9):2107-11. doi: 10.1093/jac/dkr248. Epub 2011 Jun 16.
6
Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.抗逆转录病毒治疗(HAART)同时使用细胞色素 P450 酶诱导性抗癫痫药物的病毒学结果:一项回顾性病例对照研究。
AIDS Res Ther. 2011 May 16;8:18. doi: 10.1186/1742-6405-8-18.
7
Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.非核苷类逆转录酶抑制剂、蛋白酶抑制剂和拉替拉韦为基础的抗逆转录病毒治疗方案治疗的患者中具有临床意义的药物相互作用的预测因素。
Ann Pharmacother. 2011 Mar;45(3):317-24. doi: 10.1345/aph.1P576. Epub 2011 Mar 8.
8
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.在接受含替诺福韦的联合抗逆转录病毒治疗的HIV-1感染患者中,与K65R出现相关的因素。
Clin Infect Dis. 2008 Apr 15;46(8):1299-309. doi: 10.1086/528863.
9
Drug-drug interactions among elderly patients hospitalized for drug toxicity.因药物毒性住院的老年患者中的药物相互作用。
JAMA. 2003 Apr 2;289(13):1652-8. doi: 10.1001/jama.289.13.1652.